Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f675b1162c331b357c9c2428b55a0fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69c68a76c0f543aff42aff4f02b319c5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24132 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24121 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-285 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-285 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 |
filingDate |
2017-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75c625a2fce22e95f1edc692c18ca6b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0f4f799a45e5b4d372bc37d21127039 |
publicationDate |
2021-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11104884-B2 |
titleOfInvention |
Vaccinia virus vectors related to MVA with extensive genomic symmetries |
abstract |
The present invention relates to a novel Modified Vaccinia Ankara (MVA) related virus. The present invention also relates to a method for culturing said MVA related virus and to a method for producing said MVA related virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA related virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA related virus. In addition, the present invention relates to said MVA related virus for use in medicine. |
priorityDate |
2017-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |